Sabby Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Sabby Management’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-63,060	Closed	-$157K	–	53
2024 Q3	$157K	Buy	63,060 +25,666	+69%	+$73.6K	0.08%	19
2024 Q2	$131K	Buy	37,394 +28,448	+318%	+$165K	0.09%	24
2024 Q1	$99K	Buy	+8,946	New	+$106K	0.06%	33
2023 Q3	–	Sell	-7,378	Closed	-$647K	–	108
2023 Q2	$647K	Buy	7,378 +3,646	+98%	+$300K	0.53%	17
2023 Q1	$326K	Buy	3,732 +212	+6%	+$19.6K	0.28%	37
2022 Q4	$306K	Buy	+3,520	New	+$638K	0.27%	36

Other funds holding ATXI

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Sabby Management's ATXI Position: Q4 2024 in Review

Sabby Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2024, closing a stake of 63,060 shares — an estimated $157K sold.

Sabby Management first reported a position in ATXI in Q4 2022 and held it in 6 quarters. The position peaked at $647K in Q2 2023. 7 funds tracked by Wall St. Rank hold ATXI as of Q4 2024.

Sabby Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Sabby Management sold 63,060 Avenue Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $157K.
Sabby Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2022 and held it in 6 quarters.
Sabby Management's Avenue Therapeutics, Inc. Common Stock position peaked at $647K in Q2 2023.
7 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Sabby Management's 13F filing for Q4 2024, filed 14 Feb 2025.